SGK1-IN-7 

SGK1-IN-7 is a blood-brain barrier-permeable SGK1 inhibitor with an IC₅₀ of 0.72 μM. SGK1-IN-7 reduces the phosphorylation level of TAU protein at the Ser396 and Ser214 epitopes. SGK1-IN-7 antagonizes the toxicity induced by Okadaic acid (HY-N6785). SGK1-IN-7 can be used in the research of Alzheimer's disease^[1].

SGK1-IN-7 (Compound 102) (6.25-50 μM; 30 min) is non-mutagenic and has a low cardiac safety risk, with no significant inhibition of hERG or Nav1.5 channels and moderate Cav1.2 inhibition (IC₅₀ = 12.1 μM)^[1].
SGK1-IN-7 (5 μM; 24 h) exerts significant neuroprotective effects in Okadaic acid-treated SH-SY5Y human neuroblastoma cells at 5 μM^[1].
SGK1-IN-7 (5 μM; 24 h) significantly reduces phosphorylation of tau at Ser396 and Ser214 sites in SH-SY5Y human neuroblastoma cells at 5 μM without altering total tau levels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SGK1-IN-7 (Compound 102) (2.5-10 mg/kg; i.v., i.p., p.o.; single dose) exhibits dose-dependent plasma and brain exposure in male BALB/c mice, with brain-plasma ratios (brain-Kp) of 0.49, 0.18, and 0.25 following i.v., i.p., and p.o. single-dose administration, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

385.25

C₁₉H₁₄Cl₂N₄O

3109982-58-0

O=C(C1=CN(C)C=C1C2=CC=C(Cl)C(Cl)=C2)NC3=CC4=C(NN=C4)C=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Madruga E, et al. Brain Permeable SGK1 Inhibitors: A Promising Therapeutic Strategy for Neurodegenerative Diseases. J Med Chem. 2026;69(6):6790-6815.  [Content Brief]